Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial
Portfolio Pulse from Vuk Zdinjak
Skye Bioscience, Inc. (OTCQB:SKYE) has completed the production of its cannabinoid-based drug, SBI-100, for a planned phase 2a study of glaucoma and ocular hypertension. The production was carried out by its contract manufacturer, NextPharma Oy, in Finland. The company is now working on additional logistical and preparatory steps to start the study, which is expected to begin enrollment in the third quarter.
July 06, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Skye Bioscience has completed the production of its drug for a phase 2a study, reducing science and production-related risks. The study is expected to start enrolling in the third quarter.
The completion of the drug production reduces the risks associated with the upcoming phase 2a study. This is a positive development for Skye Bioscience and could potentially have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100